Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2025 (Report No. 4)
Date: March 20, 2025
This filing serves to furnish a press release regarding the Company's updated timeline and progress with the U.S. Food and Drug Administration (FDA) concerning marketing authorization for its ProSense® device in the treatment of early-stage breast cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on regulatory updates and does not contain financial statements or quantitative financial data.
Material Changes
The primary material update disclosed is the progress made with the FDA regarding the marketing authorization for ProSense® in early-stage breast cancer. The filing incorporates specific paragraphs from the attached press release (Exhibit 99.1) by reference into the Company's existing Registration Statements on Form F-3 and Form S-8.
Guidance, Outlook, and Risks
- Outlook: The Company has issued an updated timeline for FDA marketing authorization for ProSense® in early-stage breast cancer.
- Forward-Looking Statements: The press release includes a section titled "Forward-Looking Statements," which is incorporated by reference into the Company's registration statements.
- Risks: Specific risk factors are not detailed in the body of this Form 6-K but are referenced within the incorporated press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 20, 2025) for the specific updated timeline regarding FDA marketing authorization.
- Verify the details of the "Forward-Looking Statements" incorporated into Form F-3 and Form S-8 registration statements.
- Confirm the status of the ProSense® device for early-stage breast cancer as described in the press release.